• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Dashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlerts
    Company
    AboutQuantisnow PlusContactJobs
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form SC 13G/A filed by Royalty Pharma plc (Amendment)

    2/13/24 10:17:30 AM ET
    $RPRX
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $RPRX alert in real time by email
    SC 13G/A 1 eh240447579_13ga2-rprx.htm AMENDMENT NO. 2

     

     

     

    UNITED STATES

    SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C. 20549

     

    SCHEDULE 13G

     

    Under the Securities Exchange Act of 1934

    (Amendment No. 2)*

     

    Royalty Pharma plc
    (Name of Issuer)
     
    Class A ordinary shares, par value US$0.0001 per share
    (Title of Class of Securities)
     
    G7709Q104
    (CUSIP Number)
     
    December 31, 2023
    (Date of Event Which Requires Filing of this Statement)

     

    Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

     

      ☐ Rule 13d-1(b)
      ☐ Rule 13d-1(c)
      ☒ Rule 13d-1(d)

     

    *The remainder of this cover page shall be filled out for a reporting person’s initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter disclosures provided in a prior cover page.

    The information required on the remainder of this cover page shall not be deemed to be “filed” for the purpose of Section 18 of the Securities Exchange Act of 1934 (“Act”) or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

     

     

       

     

     

    CUSIP No. G7709Q104 SCHEDULE 13G Page 2 of 30

     

     

    1

    NAME OF REPORTING PERSON

     

    General Atlantic, L.P.

     
    2

    CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP

     

     

    (a)  ☐

    (b)  ☒

    3

    SEC USE ONLY

     

     

     
    4

    CITIZENSHIP OR PLACE OF ORGANIZATION

     

    Delaware

     

    NUMBER OF

    SHARES

    BENEFICIALLY OWNED

    BY EACH REPORTING

    PERSON

    WITH

    5

    SOLE VOTING POWER

     

    0

    6

    SHARED VOTING POWER

     

    26,259,141

    7

    SOLE DISPOSITIVE POWER

     

    0

    8

    SHARED DISPOSITIVE POWER

     

    26,259,141

    9

    AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

     

    26,259,141

     
    10

    CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES

     

     

    ☐
    11

    PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)

     

    5.6%

     
    12

    TYPE OF REPORTING PERSON

     

    PN

     

     

       

     

     

    CUSIP No. G7709Q104 SCHEDULE 13G Page 3 of 30

     

     

    1

    NAME OF REPORTING PERSON

     

    General Atlantic (RP) Collections, LLC

     
    2

    CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP

     

     

    (a)  ☐

    (b)  ☒

    3

    SEC USE ONLY

     

     

     
    4

    CITIZENSHIP OR PLACE OF ORGANIZATION

     

    Delaware

     

    NUMBER OF

    SHARES

    BENEFICIALLY OWNED

    BY EACH REPORTING

    PERSON

    WITH

    5

    SOLE VOTING POWER

     

    0

    6

    SHARED VOTING POWER

     

    24,743,870

    7

    SOLE DISPOSITIVE POWER

     

    0

    8

    SHARED DISPOSITIVE POWER

     

    24,743,870

    9

    AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

     

    24,743,870

     
    10

    CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES

     

     

    ☐
    11

    PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)

     

    5.2%

     
    12

    TYPE OF REPORTING PERSON

     

    OO

     

     

       

     

     

    CUSIP No. G7709Q104 SCHEDULE 13G Page 4 of 30

     

     

    1

    NAME OF REPORTING PERSON

     

    GA RP Holding, L.P.

     
    2

    CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP

     

     

    (a)  ☐

    (b)  ☒

    3

    SEC USE ONLY

     

     

     
    4

    CITIZENSHIP OR PLACE OF ORGANIZATION

     

    Bermuda

     

    NUMBER OF

    SHARES

    BENEFICIALLY OWNED

    BY EACH REPORTING

    PERSON

    WITH

    5

    SOLE VOTING POWER

     

    0

    6

    SHARED VOTING POWER

     

    1,500,000

    7

    SOLE DISPOSITIVE POWER

     

    0

    8

    SHARED DISPOSITIVE POWER

     

    1,500,000

    9

    AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

     

    1,500,000

     
    10

    CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES

     

     

    ☐
    11

    PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)

     

    0.3%

     
    12

    TYPE OF REPORTING PERSON

     

    PN

     

     

       

     

     

    CUSIP No. G7709Q104 SCHEDULE 13G Page 5 of 30

     

     

    1

    NAME OF REPORTING PERSON

     

    General Atlantic Partners AIV-1 A, L.P.

     
    2

    CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP

     

     

    (a)  ☐

    (b)  ☒

    3

    SEC USE ONLY

     

     

     
    4

    CITIZENSHIP OR PLACE OF ORGANIZATION

     

    Delaware

     

    NUMBER OF

    SHARES

    BENEFICIALLY OWNED

    BY EACH REPORTING

    PERSON

    WITH

    5

    SOLE VOTING POWER

     

    0

    6

    SHARED VOTING POWER

     

    24,743,870

    7

    SOLE DISPOSITIVE POWER

     

    0

    8

    SHARED DISPOSITIVE POWER

     

    24,743,870

    9

    AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

     

    24,743,870

     
    10

    CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES

     

     

    ☐
    11

    PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)

     

    5.2%

     
    12

    TYPE OF REPORTING PERSON

     

    PN

     

     

       

     

     

    CUSIP No. G7709Q104 SCHEDULE 13G Page 6 of 30

     

     

    1

    NAME OF REPORTING PERSON

     

    General Atlantic Partners AIV-1 B, L.P.

     
    2

    CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP

     

     

    (a)  ☐

    (b)  ☒

    3

    SEC USE ONLY

     

     

     
    4

    CITIZENSHIP OR PLACE OF ORGANIZATION

     

    Delaware

     

    NUMBER OF

    SHARES

    BENEFICIALLY OWNED

    BY EACH REPORTING

    PERSON

    WITH

    5

    SOLE VOTING POWER

     

    0

    6

    SHARED VOTING POWER

     

    24,743,870

    7

    SOLE DISPOSITIVE POWER

     

    0

    8

    SHARED DISPOSITIVE POWER

     

    24,743,870

    9

    AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

     

    24,743,870

     
    10

    CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES

     

     

    ☐
    11

    PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)

     

    5.2%

     
    12

    TYPE OF REPORTING PERSON

     

    PN

     

     

       

     

     

    CUSIP No. G7709Q104 SCHEDULE 13G Page 7 of 30

     

     

    1

    NAME OF REPORTING PERSON

     

    GAP Coinvestments CDA, L.P.

     
    2

    CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP

     

     

    (a)  ☐

    (b)  ☒

    3

    SEC USE ONLY

     

     

     
    4

    CITIZENSHIP OR PLACE OF ORGANIZATION

     

    Delaware

     

    NUMBER OF

    SHARES

    BENEFICIALLY OWNED

    BY EACH REPORTING

    PERSON

    WITH

    5

    SOLE VOTING POWER

     

    0

    6

    SHARED VOTING POWER

     

    26,243,870

    7

    SOLE DISPOSITIVE POWER

     

    0

    8

    SHARED DISPOSITIVE POWER

     

    26,243,870

    9

    AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

     

    26,243,870

     
    10

    CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES

     

     

    ☐
    11

    PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)

     

    5.6%

     
    12

    TYPE OF REPORTING PERSON

     

    PN

     

     

       

     

     

    CUSIP No. G7709Q104 SCHEDULE 13G Page 8 of 30

     

     

    1

    NAME OF REPORTING PERSON

     

    GAP Coinvestments III, LLC

     
    2

    CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP

     

     

    (a)  ☐

    (b)  ☒

    3

    SEC USE ONLY

     

     

     
    4

    CITIZENSHIP OR PLACE OF ORGANIZATION

     

    Delaware

     

    NUMBER OF

    SHARES

    BENEFICIALLY OWNED

    BY EACH REPORTING

    PERSON

    WITH

    5

    SOLE VOTING POWER

     

    0

    6

    SHARED VOTING POWER

     

    26,243,870

    7

    SOLE DISPOSITIVE POWER

     

    0

    8

    SHARED DISPOSITIVE POWER

     

    26,243,870

    9

    AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

     

    26,243,870

     
    10

    CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES

     

     

    ☐
    11

    PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)

     

    5.6%

     
    12

    TYPE OF REPORTING PERSON

     

    OO

     

     

       

     

     

    CUSIP No. G7709Q104 SCHEDULE 13G Page 9 of 30

     

     

    1

    NAME OF REPORTING PERSON

     

    GAP Coinvestments IV, LLC

     
    2

    CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP

     

     

    (a)  ☐

    (b)  ☒

    3

    SEC USE ONLY

     

     

     
    4

    CITIZENSHIP OR PLACE OF ORGANIZATION

     

    Delaware

     

    NUMBER OF

    SHARES

    BENEFICIALLY OWNED

    BY EACH REPORTING

    PERSON

    WITH

    5

    SOLE VOTING POWER

     

    0

    6

    SHARED VOTING POWER

     

    26,243,870

    7

    SOLE DISPOSITIVE POWER

     

    0

    8

    SHARED DISPOSITIVE POWER

     

    26,243,870

    9

    AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

     

    26,243,870

     
    10

    CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES

     

     

    ☐
    11

    PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)

     

    5.6%

     
    12

    TYPE OF REPORTING PERSON

     

    OO

     

     

       

     

     

    CUSIP No. G7709Q104 SCHEDULE 13G Page 10 of 30

     

     

    1

    NAME OF REPORTING PERSON

     

    GAP Coinvestments V, LLC

     
    2

    CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP

     

     

    (a)  ☐

    (b)  ☒

    3

    SEC USE ONLY

     

     

     
    4

    CITIZENSHIP OR PLACE OF ORGANIZATION

     

    Delaware

     

    NUMBER OF

    SHARES

    BENEFICIALLY OWNED

    BY EACH REPORTING

    PERSON

    WITH

    5

    SOLE VOTING POWER

     

    0

    6

    SHARED VOTING POWER

     

    26,243,870

    7

    SOLE DISPOSITIVE POWER

     

    0

    8

    SHARED DISPOSITIVE POWER

     

    26,243,870

    9

    AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

     

    26,243,870

     
    10

    CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES

     

     

    ☐
    11

    PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)

     

    5.6%

     
    12

    TYPE OF REPORTING PERSON

     

    OO

     

     

       

     

     

    CUSIP No. G7709Q104 SCHEDULE 13G Page 11 of 30

     

     

    1

    NAME OF REPORTING PERSON

     

    General Atlantic (SPV) GP, LLC

     
    2

    CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP

     

     

    (a)  ☐

    (b)  ☒

    3

    SEC USE ONLY

     

     

     
    4

    CITIZENSHIP OR PLACE OF ORGANIZATION

     

    Delaware

     

    NUMBER OF

    SHARES

    BENEFICIALLY OWNED

    BY EACH REPORTING

    PERSON

    WITH

    5

    SOLE VOTING POWER

     

    0

    6

    SHARED VOTING POWER

     

    24,743,870

    7

    SOLE DISPOSITIVE POWER

     

    0

    8

    SHARED DISPOSITIVE POWER

     

    24,743,870

    9

    AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

     

    24,743,870

     
    10

    CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES

     

     

    ☐
    11

    PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)

     

    5.2%

     
    12

    TYPE OF REPORTING PERSON

     

    OO

     

     

       

     

     

    CUSIP No. G7709Q104 SCHEDULE 13G Page 12 of 30

     

     

    1

    NAME OF REPORTING PERSON

     

    General Atlantic GenPar, L.P.

     
    2

    CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP

     

     

    (a)  ☐

    (b)  ☒

    3

    SEC USE ONLY

     

     

     
    4

    CITIZENSHIP OR PLACE OF ORGANIZATION

     

    Delaware

     

    NUMBER OF

    SHARES

    BENEFICIALLY OWNED

    BY EACH REPORTING

    PERSON

    WITH

    5

    SOLE VOTING POWER

     

    0

    6

    SHARED VOTING POWER

     

    24,743,870

    7

    SOLE DISPOSITIVE POWER

     

    0

    8

    SHARED DISPOSITIVE POWER

     

    24,743,870

    9

    AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

     

    24,743,870

     
    10

    CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES

     

     

    ☐
    11

    PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)

     

    5.2%

     
    12

    TYPE OF REPORTING PERSON

     

    PN

     

     

       

     

     

    CUSIP No. G7709Q104 SCHEDULE 13G Page 13 of 30

     

     

    1

    NAME OF REPORTING PERSON

     

    General Atlantic Partners (Bermuda) EU, L.P.

     
    2

    CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP

     

     

    (a)  ☐

    (b)  ☒

    3

    SEC USE ONLY

     

     

     
    4

    CITIZENSHIP OR PLACE OF ORGANIZATION

     

    Bermuda

     

    NUMBER OF

    SHARES

    BENEFICIALLY OWNED

    BY EACH REPORTING

    PERSON

    WITH

    5

    SOLE VOTING POWER

     

    0

    6

    SHARED VOTING POWER

     

    1,500,000

    7

    SOLE DISPOSITIVE POWER

     

    0

    8

    SHARED DISPOSITIVE POWER

     

    1,500,000

    9

    AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

     

    1,500,000

     
    10

    CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES

     

     

    ☐
    11

    PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)

     

    0.3%

     
    12

    TYPE OF REPORTING PERSON

     

    PN

     

     

       

     

     

    CUSIP No. G7709Q104 SCHEDULE 13G Page 14 of 30

     

     

    1

    NAME OF REPORTING PERSON

     

    General Atlantic Partners (Bermuda) IV, L.P.

     
    2

    CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP

     

     

    (a)  ☐

    (b)  ☒

    3

    SEC USE ONLY

     

     

     
    4

    CITIZENSHIP OR PLACE OF ORGANIZATION

     

    Bermuda

     

    NUMBER OF

    SHARES

    BENEFICIALLY OWNED

    BY EACH REPORTING

    PERSON

    WITH

    5

    SOLE VOTING POWER

     

    0

    6

    SHARED VOTING POWER

     

    1,500,000

    7

    SOLE DISPOSITIVE POWER

     

    0

    8

    SHARED DISPOSITIVE POWER

     

    1,500,000

    9

    AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

     

    1,500,000

     
    10

    CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES

     

     

    ☐
    11

    PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)

     

    0.3%

     
    12

    TYPE OF REPORTING PERSON

     

    PN

     

     

       

     

     

    CUSIP No. G7709Q104 SCHEDULE 13G Page 15 of 30

     

     

    1

    NAME OF REPORTING PERSON

     

    General Atlantic Partners (Lux) SCSp

     
    2

    CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP

     

     

    (a)  ☐

    (b)  ☒

    3

    SEC USE ONLY

     

     

     
    4

    CITIZENSHIP OR PLACE OF ORGANIZATION

     

    Luxembourg

     

    NUMBER OF

    SHARES

    BENEFICIALLY OWNED

    BY EACH REPORTING

    PERSON

    WITH

    5

    SOLE VOTING POWER

     

    0

    6

    SHARED VOTING POWER

     

    1,500,000

    7

    SOLE DISPOSITIVE POWER

     

    0

    8

    SHARED DISPOSITIVE POWER

     

    1,500,000

    9

    AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

     

    1,500,000

     
    10

    CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES

     

     

    ☐
    11

    PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)

     

    0.3%

     
    12

    TYPE OF REPORTING PERSON

     

    PN

     

     

       

     

     

    CUSIP No. G7709Q104 SCHEDULE 13G Page 16 of 30

     

     

    1

    NAME OF REPORTING PERSON

     

    General Atlantic GenPar (Lux) SCSp

     
    2

    CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP

     

     

    (a)  ☐

    (b)  ☒

    3

    SEC USE ONLY

     

     

     
    4

    CITIZENSHIP OR PLACE OF ORGANIZATION

     

    Luxembourg

     

    NUMBER OF

    SHARES

    BENEFICIALLY OWNED

    BY EACH REPORTING

    PERSON

    WITH

    5

    SOLE VOTING POWER

     

    0

    6

    SHARED VOTING POWER

     

    1,500,000

    7

    SOLE DISPOSITIVE POWER

     

    0

    8

    SHARED DISPOSITIVE POWER

     

    1,500,000

    9

    AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

     

    1,500,000

     
    10

    CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES

     

     

    ☐
    11

    PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)

     

    0.3%

     
    12

    TYPE OF REPORTING PERSON

     

    PN

     

     

       

     

     

    CUSIP No. G7709Q104 SCHEDULE 13G Page 17 of 30

     

     

    1

    NAME OF REPORTING PERSON

     

    General Atlantic (Lux) S.à.r.l.

     
    2

    CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP

     

     

    (a)  ☐

    (b)  ☒

    3

    SEC USE ONLY

     

     

     
    4

    CITIZENSHIP OR PLACE OF ORGANIZATION

     

    Luxembourg

     

    NUMBER OF

    SHARES

    BENEFICIALLY OWNED

    BY EACH REPORTING

    PERSON

    WITH

    5

    SOLE VOTING POWER

     

    0

    6

    SHARED VOTING POWER

     

    1,500,000

    7

    SOLE DISPOSITIVE POWER

     

    0

    8

    SHARED DISPOSITIVE POWER

     

    1,500,000

    9

    AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

     

    1,500,000

     
    10

    CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES

     

     

    ☐
    11

    PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)

     

    0.3%

     
    12

    TYPE OF REPORTING PERSON

     

    CO

     

     

       

     

     

    CUSIP No. G7709Q104 SCHEDULE 13G Page 18 of 30

     

     

    1

    NAME OF REPORTING PERSON

     

    General Atlantic GenPar (Bermuda), L.P.

     
    2

    CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP

     

     

    (a)  ☐

    (b)  ☒

    3

    SEC USE ONLY

     

     

     
    4

    CITIZENSHIP OR PLACE OF ORGANIZATION

     

    Bermuda

     

    NUMBER OF

    SHARES

    BENEFICIALLY OWNED

    BY EACH REPORTING

    PERSON

    WITH

    5

    SOLE VOTING POWER

     

    0

    6

    SHARED VOTING POWER

     

    1,500,000

    7

    SOLE DISPOSITIVE POWER

     

    0

    8

    SHARED DISPOSITIVE POWER

     

    1,500,000

    9

    AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

     

    1,500,000

     
    10

    CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES

     

     

    ☐
    11

    PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)

     

    0.3%

     
    12

    TYPE OF REPORTING PERSON

     

    PN

     

     

       

     

     

    CUSIP No. G7709Q104 SCHEDULE 13G Page 19 of 30

     

     

    1

    NAME OF REPORTING PERSON

     

    GAP (Bermuda) L.P.

     
    2

    CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP

     

     

    (a)  ☐

    (b)  ☒

    3

    SEC USE ONLY

     

     

     
    4

    CITIZENSHIP OR PLACE OF ORGANIZATION

     

    Bermuda

     

    NUMBER OF

    SHARES

    BENEFICIALLY OWNED

    BY EACH REPORTING

    PERSON

    WITH

    5

    SOLE VOTING POWER

     

    0

    6

    SHARED VOTING POWER

     

    1,500,000

    7

    SOLE DISPOSITIVE POWER

     

    0

    8

    SHARED DISPOSITIVE POWER

     

    1,500,000

    9

    AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

     

    1,500,000

     
    10

    CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES

     

     

    ☐
    11

    PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)

     

    0.3%

     
    12

    TYPE OF REPORTING PERSON

     

    PN

     

     

       

     

     

    CUSIP No. G7709Q104 SCHEDULE 13G Page 20 of 30

     

     

    1

    NAME OF REPORTING PERSON

     

    GA RP Holding, Ltd.

     
    2

    CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP

     

     

    (a)  ☐

    (b)  ☒

    3

    SEC USE ONLY

     

     

     
    4

    CITIZENSHIP OR PLACE OF ORGANIZATION

     

    Bermuda

     

    NUMBER OF

    SHARES

    BENEFICIALLY OWNED

    BY EACH REPORTING

    PERSON

    WITH

    5

    SOLE VOTING POWER

     

    0

    6

    SHARED VOTING POWER

     

    1,500,000

    7

    SOLE DISPOSITIVE POWER

     

    0

    8

    SHARED DISPOSITIVE POWER

     

    1,500,000

    9

    AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

     

    1,500,000

     
    10

    CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES

     

     

    ☐
    11

    PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)

     

    0.3%

     
    12

    TYPE OF REPORTING PERSON

     

    CO

     

     

       

     

     

    CUSIP No. G7709Q104 SCHEDULE 13G Page 21 of 30

     

     

    Item 1. (a) NAME OF ISSUER
         
        Royalty Pharma plc (the “Company”).
         
      (b) ADDRESS OF ISSUER’S PRINCIPAL EXECUTIVE OFFICES
         
        110 East 59th Street, New York, NY 10022.
         
    Item 2. (a) NAMES OF PERSONS FILING
         
        This Statement is being filed on behalf of each of the following persons (collectively, the “Reporting Persons”):

     

      (i) General Atlantic, L.P. (“GA LP”);
         
      (ii) General Atlantic (RP) Collections, LLC (“GA RP Collections”);
         
      (iii) GA RP Holding, L.P. (“GA RP Holding”);
         
      (iv) General Atlantic Partners AIV-1 A, L.P. (“GAP AIV-1 A”);
         
      (v) General Atlantic Partners AIV-1 B, L.P. (“GAP AIV-1 B”);
         
      (vi) GAP Coinvestments CDA, L.P. (“GAPCO CDA”);
         
      (vii) GAP Coinvestments III, LLC (“GAPCO III”);
         
      (viii) GAP Coinvestments IV, LLC (“GAPCO IV”);
         
      (ix) GAP Coinvestments V, LLC (“GAPCO V”);
         
      (x) General Atlantic (SPV) GP, LLC (“GA SPV”);
         
      (xi) General Atlantic GenPar, L.P. (“GenPar”);
         
      (xii) General Atlantic Partners (Bermuda) EU, L.P. (“GAP EU”);
         
      (xiii) General Atlantic Partners (Bermuda) IV, L.P. (“GAP IV”);
         
      (xiv) General Atlantic Partners (Lux) SCSp (“GAP Lux”);
         
      (xv) General Atlantic GenPar (Lux) SCSp (“GAP GenPar Lux”);
         
      (xvi) General Atlantic (Lux) S.à.r.l. (“GA Lux”);
         
      (xvii) General Atlantic GenPar (Bermuda), L.P. (“GenPar Bermuda”);
         
      (xviii) GAP (Bermuda) L.P. (“GAP (Bermuda) L.P.”); and
         
      (xix) GA RP Holding, Ltd. (“GA RP Holding, Ltd.”).

     

       

     

     

    CUSIP No. G7709Q104 SCHEDULE 13G Page 22 of 30

     

     

      (b) ADDRESS OF PRINCIPAL BUSINESS OFFICE
         
       

    The principal address of each of the Reporting Persons (other than GAP Lux, GAP GenPar Lux and GA Lux) is c/o General Atlantic Service Company, L.P., 55 East 52nd Street, 33rd Floor, New York, NY 10055. The principal address of each of GAP Lux, GAP GenPar Lux and GA Lux is 412F, route d’Esch, L-1471 Luxembourg, Grand Duchy of Luxembourg.

         
      (c) CITIZENSHIP

     

      (i) GA LP – Delaware
         
      (ii) GA RP Collections – Delaware
         
      (iii) GA RP Holding – Bermuda
         
      (iv) GA AIV-1 A – Delaware
         
      (v) GAP AIV-1 B – Delaware
         
      (vi) GAPCO CDA – Delaware
         
      (vii) GAPCO III – Delaware
         
      (viii) GAPCO IV – Delaware
         
      (ix) GAPCO V – Delaware
         
      (x) GA SPV – Delaware
         
      (xi) GenPar – Delaware
         
      (xii) GAP EU – Bermuda
         
      (xiii) GAP IV– Bermuda
         
      (xiv) GAP Lux – Luxembourg
         
      (xv) GAP GenPar Lux – Luxembourg
         
      (xvi) GA Lux – Luxembourg
         
      (xvii) GenPar Bermuda – Bermuda
         
      (xviii) GAP (Bermuda) L.P. – Bermuda
         
      (xix) GA RP Holding, Ltd. – Bermuda

     

       

     

     

    CUSIP No. G7709Q104 SCHEDULE 13G Page 23 of 30

     

     

      (d) TITLE OF CLASS OF SECURITIES
         
        Class A ordinary shares, par value US$0.0001 per share (the “Class A ordinary shares”)
         
      (e) CUSIP NUMBER
         
        G7709Q104

     

    Item 3.  IF THIS STATEMENT IS FILED PURSUANT TO RULES 13d-1(b) OR 13d-2(b) OR (c), CHECK WHETHER THE PERSON FILING IS:
       
      Not applicable.
       
    Item 4.  OWNERSHIP.
       
     

    As of December 31, 2023, the Reporting Persons owned the following number of the Company’s Class A ordinary shares:

     

      (i) GA LP owned of record 15,271 Class A ordinary shares or 0.0% of the issued and outstanding Class A ordinary shares
         
      (ii) GA RP Collections has an indirect ownership interest in 24,743,870 Class B ordinary shares of the Company corresponding to an equal number of Class B interests of Royalty Pharma Holdings Ltd, a subsidiary of the Company, each convertible at the option of the holder into one Class A ordinary shares, or approximately 5.2% of the issued and outstanding Class A ordinary shares
         
      (iii) GA RP Holding owned of record 1,500,000 Class A ordinary shares or 0.3% of the issued and outstanding Class A ordinary shares
         
      (iv) GAP AIV-1 A owned of record no Class A ordinary shares or 0.0% of the issued and outstanding Class A ordinary shares
         
      (v) GAP AIV-1 B owned of record no Class A ordinary shares or 0.0% of the issued and outstanding Class A ordinary shares
         
      (vi) GAPCO CDA owned of record no Class A ordinary shares or 0.0% of the issued and outstanding Class A ordinary shares
         
      (vii) GAPCO III owned of record no Class A ordinary shares or 0.0% of the issued and outstanding Class A ordinary shares
         
      (viii) GAPCO IV owned of record no Class A ordinary shares or 0.0% of the issued and outstanding Class A ordinary shares
         
      (ix) GAPCO V owned of record no Class A ordinary shares or 0.0% of the issued and outstanding Class A ordinary shares
         
      (x) GA SPV owned of record no Class A ordinary shares or 0.0% of the issued and outstanding Class A ordinary shares

     

       

     

     

    CUSIP No. G7709Q104 SCHEDULE 13G Page 24 of 30

     

     

      (xi) GenPar owned of record no Class A ordinary shares or 0.0% of the issued and outstanding Class A ordinary shares

     

      (xii) GAP EU owned of record no Class A ordinary shares or 0.0% of the issued and outstanding Class A ordinary shares
         
      (xiii) GAP IV owned of record no Class A ordinary shares or 0.0% of the issued and outstanding Class A ordinary shares
         
      (xiv) GAP Lux owned of record no Class A ordinary shares or 0.0% of the issued and outstanding Class A ordinary shares
         
      (xv) GAP GenPar Lux owned of record no Class A ordinary shares or 0.0% of the issued and outstanding Class A ordinary shares
         
      (xvi) GA Lux owned of record no Class A ordinary shares or 0.0% of the issued and outstanding Class A ordinary shares
         
      (xvii) GenPar Bermuda owned of record no Class A ordinary shares or 0.0% of the issued and outstanding Class A ordinary shares
         
      (xviii) GAP (Bermuda) L.P. owned of record no Class A ordinary shares or 0.0% of the issued and outstanding Class A ordinary shares
         
      (xix) GA RP Holding, Ltd. owned of record no Class A ordinary shares or 0.0% of the issued and outstanding Class A ordinary shares
         
     

    The members of GA RP Collections that share beneficial ownership of the Class A ordinary shares held of record by GA RP Collections are indirectly held by the following General Atlantic investment funds, (the “GA Funds”): GAP AIV-1 A, GAP AIV-1 B, GAPCO CDA, GAPCO III, GAPCO IV and GAPCO V. GA SPV is the sole non-member manager of GA RP Collections. The general partner of GAP AIV-1 A and GAP AIV-1 B is GenPar. The general partner of GenPar is GA LP. GA LP is the sole member of GA SPV, the managing member of GAPCO III, GAPCO IV and GAPCO V and the general partner of GAPCO CDA. The limited partners that share beneficial ownership of the Class A ordinary shares held by GA RP Holding are the following General Atlantic investment funds: GAP EU, GAP IV, GAP Lux, GAPCO III, GAPCO IV, GAPCO V and GAPCO CDA. The general partner of GAP Lux is GAP GenPar Lux and the general partner of GAP GenPar Lux is GA Lux. The general partner of GAP EU, GAP IV and GA Lux is GenPar Bermuda. GAP (Bermuda) L.P. is the general partner of GenPar Bermuda. The general partner of GA RP Holding is GA RP Holding, Ltd. (“GA RP Holding, Ltd.”). GAP (Bermuda) L.P. is the sole shareholder of GA RP Holding, Ltd. GA LP and GAP (Bermuda) L.P. are controlled by the Management Committee of GASC MGP, LLC (the “GA Management Committee”). There are eleven members of the GA Management Committee. GA LP, GAP (Bermuda) L.P., GA RP Holdings Ltd., GenPar Bermuda, GA Lux, GAP GenPar Lux, GAP Lux, GAP IV, GAP EU, GenPar, GA SPV, GAP AIV-1 A, GAP AIV-1 B, GAPCO III, GAPCO IV, GAPCO V, GAPCO CDA are a “group” within the meaning of Rule 13d-5 of the Securities Exchange Act of 1934, as amended. Each of the members of the GA Management Committee disclaims ownership of the Class A ordinary shares reported herein except to the extent he has a pecuniary interest therein. The name, the business address and the citizenship of each of the members of the GA Management Committee as of the date hereof is attached hereto as Schedule A and is hereby incorporated by reference.

     

    Amount Beneficially Owned:

    By virtue of the relationship described above, each of the Reporting Persons may be deemed to beneficially own the Class A ordinary shares indicated on row (9) on such Reporting Person’s cover page included herein.

     

       

     

     

    CUSIP No. G7709Q104 SCHEDULE 13G Page 25 of 30

     

     

    Percentage Owned:

    All calculation of percentage ownership herein are based on an aggregate of 471,432,679 Class A ordinary shares outstanding, consisting of (i) 446,688,809 Class A ordinary shares reported by the Company to be outstanding as of November 13, 2023, as reflected in the Company’s prospectus filed under Rule 424(b)(7), filed with the U.S. Securities and Exchange Commission on November 16, 2023, and (ii) 24,743,870 Class A ordinary shares issuable upon conversion of Class B interests of Royalty Pharma Holdings held by GA RP Collections.

     

    Number of Shares as to Which Such Person Has Sole/Shared Power to Vote or to Direct the Vote and Sole/Shared Power to Dispose or to Direct the Disposition of:

       
      (i) Each of the Reporting Persons may be deemed to have the sole power to direct the voting and dispositions of the Class A ordinary shares as indicated on such Reporting Person’s cover page included herein.
         
      (ii) Each of the Reporting Persons may be deemed to share the power to direct the voting and dispositions of the Class A ordinary shares as indicated on such Reporting Person’s cover page included herein.

     

    Item 5. OWNERSHIP OF FIVE PERCENT OR LESS OF A CLASS
       
      Not applicable.

     

    Item 6. OWNERSHIP OF MORE THAN FIVE PERCENT ON BEHALF OF ANOTHER PERSON
       
      Not applicable.
       
    Item 7. IDENTIFICATION AND CLASSIFICATION OF THE SUBSIDIARY WHICH ACQUIRED THE SECURITY BEING REPORTED ON BY THE PARENT HOLDING COMPANY
       
      Not applicable.
       
    Item 8. IDENTIFICATION AND CLASSIFICATION OF MEMBERS OF THE GROUP
       
      See Item 2, which states the identity of the members of the group filing this Schedule 13G.
       
    Item 9. NOTICE OF DISSOLUTION OF GROUP
       
      Not applicable.
       
    Item 10. CERTIFICATION
       
      Not applicable.

     

       

     

     

    CUSIP No. G7709Q104 SCHEDULE 13G Page 26 of 30

     

     

    Exhibit Index

     

    Exhibit 1

    Joint Filing Agreement as required by Rule 13d-1(k)(1) under the Securities Exchange Act of 1934, as amended (previously filed).

     

     

     

     

       

     

     

    CUSIP No. G7709Q104 SCHEDULE 13G Page 27 of 30

     

     

    SIGNATURES

     

    After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

     

    Dated as of February 13, 2024

     

     

    GENERAL ATLANTIC, L.P.

     
             
      By: /s/ Michael Gosk  
        Name:

    Michael Gosk

     
        Title:

    Managing Director

     

     

     

     

    GENERAL ATLANTIC (RP) COLLECTIONS, LLC

     
           
      By:

    GENERAL ATLANTIC (SPV) GP, LLC, its sole non-member manager

     
             
      By: /s/ Michael Gosk  
        Name: Michael Gosk  
        Title: Managing Director  
             
             
     

    GA RP HOLDING, L.P.

     
             
      By:

    GA RP HOLDING, LTD, its general partner

     
           
      By: /s/ Michael Gosk  
        Name: Michael Gosk  
        Title: Director  
             
             
     

    GENERAL ATLANTIC PARTNERS AIV-1 A, L.P.

     
             
      By:

    GENERAL ATLANTIC GENPAR, L.P., its general partner 

     
             
      By:

    GENERAL ATLANTIC, L.P., its general partner

     
             
      By: /s/ Michael Gosk  
        Name: Michael Gosk  
        Title: Managing Director  
         
         
     

    GENERAL ATLANTIC PARTNERS A1V-1 B, L.P.

     
             
      By:

    GENERAL ATLANTIC GENPAR, L.P., its general partner 

     
             
      By:

    GENERAL ATLANTIC, L.P., its general partner

     
             
      By: /s/ Michael Gosk  
        Name: Michael Gosk  
        Title: Managing Director  

     

       

     

     

    CUSIP No. G7709Q104 SCHEDULE 13G Page 28 of 30

     

     

     

    GAP COINVESTMENTS CDA, L.P.

     
             
      By:

    GENERAL ATLANTIC, L.P., its general partner 

     
             
      By: /s/ Michael Gosk  
        Name: Michael Gosk  
        Title: Managing Director  
             
             
     

    GAP COINVESTMENTS III, LLC

     
             
      By:

    GENERAL ATLANTIC, L.P., its managing member

     
             
      By: /s/ Michael Gosk  
        Name:

    Michael Gosk

     
        Title: Managing Director  
             
         
     

    GAP COINVESTMENTS IV, LLC

     
             
      By:

    GENERAL ATLANTIC, L.P., its managing member

     
             
      By: /s/ Michael Gosk  
        Name: Michael Gosk  
        Title: Managing Director  
         
         
     

    GAP COINVESTMENTS V, LLC

     
             
      By:

    GENERAL ATLANTIC, L.P., its managing member 

     
             
      By: /s/ Michael Gosk  
        Name: Michael Gosk  
        Title: Managing Director  
       
     
     

    GENERAL ATLANTIC (SPV) GP, LLC

     
             
      By:

    GENERAL ATLANTIC, L.P., its sole member 

     
             
      By: /s/ Michael Gosk  
        Name: Michael Gosk  
        Title: Managing Director  
     
         
     

    GENERAL ATLANTIC GENPAR, L.P.

     
             
      By:

    GENERAL ATLANTIC, L.P., its general partner 

     
             
      By: /s/ Michael Gosk  
        Name: Michael Gosk  
        Title: Managing Director  

     

       

     

     

    CUSIP No. G7709Q104 SCHEDULE 13G Page 29 of 30

     

     

     

    GENERAL ATLANTIC PARTNERS (BERMUDA) EU, L.P.

     
             
      By:

    GENERAL ATLANTIC GENPAR (BERMUDA), L.P., its general partner 

     
           
      By:

    GAP (BERMUDA) L.P., its general partner

     
           
      By: GAP (BERMUDA) GP LIMITED, its general partner  
             
      By: /s/ Michael Gosk  
        Name: Michael Gosk  
        Title: Managing Director  
             
         
     

    GENERAL ATLANTIC PARTNERS (BERMUDA) IV, L.P.

     
             
      By:

    GENERAL ATLANTIC GENPAR (BERMUDA), L.P., its general partner 

     
           
      By: GAP (BERMUDA) L.P., its general partner  
           
      By: /s/ Michael Gosk  
        Name: Michael Gosk  
        Title: Managing Director  
             
         
     

    GENERAL ATLANTIC PARTNERS (LUX) SCSP

     
             
      By:

    GENERAL ATLANTIC GENPAR (LUX) SCSP, its general partner 

     
           
      By: GENERAL ATLANTIC (LUX) S.À R.L., its general partner   
           
      By: /s/ Ingrid van der Hoorn  
        Name: Ingrid van der Hoorn  
        Title: Manager A  
             
      By: /s/ William Blackwell  
        Name:

    William Blackwell

     
        Title: Manager B  
         

     

     

    GENERAL ATLANTIC GENPAR (LUX) SCSP

     
             
      By:

    GENERAL ATLANTIC (LUX) S.À R.L., its general partner 

     
             
      By: /s/ Ingrid van der Hoorn  
        Name:

    Ingrid van der Hoorn

     
        Title: Manager A  
         
      By: /s/ William Blackwell  
        Name:

    William Blackwell

     
        Title: Manager B  

     

       

     

     

    CUSIP No. G7709Q104 SCHEDULE 13G Page 30 of 30

     

             
     

    GENERAL ATLANTIC (LUX) S.À R.L.

     
             
      By: /s/ Ingrid van der Hoorn  
        Name: Ingrid van der Hoorn  
        Title: Manager A  
             
      By: /s/ William Blackwell  
        Name:

    William Blackwell

     
        Title: Manager B  
             
     

    GENERAL ATLANTIC GENPAR (BERMUDA), L.P.

     
             
      By:

    GAP (BERMUDA) L.P., its general partner

     
           
      By: GAP (BERMUDA) GP LIMITED, its general partner  
             
      By: /s/ Michael Gosk  
        Name:

    Michael Gosk

     
        Title:

    Managing Director

     
             
         
     

    GAP (BERMUDA) L.P.

     
             
      By:

    GAP (BERMUDA) GP LIMITED, its general partner

     
             
      By: /s/ Michael Gosk  
        Name: Michael Gosk  
        Title: Managing Director  
     
         
     

    GA RP HOLDING, LTD.

     
             
      By: /s/ Michael Gosk  
        Name: Michael Gosk  
        Title: Director  

     

       

     

     

    SCHEDULE A

     

    Members of the Management Committee (as of the date hereof)

     

    Name Address Citizenship

    William E. Ford

    (Chief Executive Officer)

    55 East 52nd Street

    33rd Floor

    New York, New York 10055

    United States
    Gabriel Caillaux

    23 Savile Row

    London W1S 2ET

    United Kingdom

    France
    Andrew Crawford

    55 East 52nd Street

    33rd Floor

    New York, New York 10055

    United States
    Martin Escobari

    55 East 52nd Street

    33rd Floor

    New York, New York 10055

    Bolivia and Brazil
    Anton J. Levy

    55 East 52nd Street

    33rd Floor

    New York, New York 10055

    United States
    Sandeep Naik

    Marina Bay Financial Centre Tower 1

    8 Marina Boulevard, #17-02

    018981, Singapore

    United States
    J. Albert Smith

    535 Madison Ave,

    31st Floor

    New York, New York 10022

    United States
    Graves Tompkins

    55 East 52nd Street

    33rd Floor

    New York, New York 10055

    United States
    Lance D. G. Uggla

    23 Savile Row

    London W1S 2ET

    United Kingdom

    United Kingdom and Canada
    N. Robbert Vorhoff

    55 East 52nd Street

    33rd Floor

    New York, New York 10055

    United States
    Eric Zhang

    Suite 5704-5706, 57F

    Two IFC, 8 Finance Street

    Central, Hong Kong, China

    Hong Kong SAR

     

     

      

     

    Get the next $RPRX alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $RPRX

    DatePrice TargetRatingAnalyst
    6/3/2024$28.00Buy → Neutral
    UBS
    6/14/2022$47.00Buy
    UBS
    5/13/2022$53.00Sector Outperform
    Scotiabank
    4/27/2022$56.00Buy
    Goldman
    4/14/2022$50.00Neutral → Overweight
    JP Morgan
    4/6/2022$48.00Overweight
    Morgan Stanley
    10/29/2021$50.00Neutral → Buy
    Citigroup
    8/16/2021$51.00 → $46.00Equal-Weight
    Morgan Stanley
    More analyst ratings

    $RPRX
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • CEO, Chairman of the Board Legorreta Pablo G. was granted 288,352 units of Class A Ordinary Shares, increasing direct ownership by 452% to 352,147 units (SEC Form 4)

      4 - Royalty Pharma plc (0001802768) (Issuer)

      5/9/25 5:18:28 PM ET
      $RPRX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • EVP, Investments & CLO Lloyd George W. was granted 48,646 units of Class A Ordinary Shares (SEC Form 4)

      4 - Royalty Pharma plc (0001802768) (Issuer)

      5/9/25 5:15:40 PM ET
      $RPRX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • EVP & Vice Chairman Hite Christopher was granted 48,646 units of Class A Ordinary Shares (SEC Form 4)

      4 - Royalty Pharma plc (0001802768) (Issuer)

      5/9/25 5:14:15 PM ET
      $RPRX
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $RPRX
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • Royalty Pharma downgraded by UBS with a new price target

      UBS downgraded Royalty Pharma from Buy to Neutral and set a new price target of $28.00

      6/3/24 9:17:33 AM ET
      $RPRX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • UBS resumed coverage on Royalty Pharma with a new price target

      UBS resumed coverage of Royalty Pharma with a rating of Buy and set a new price target of $47.00

      6/14/22 7:27:46 AM ET
      $RPRX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Scotiabank initiated coverage on Royalty Pharma with a new price target

      Scotiabank initiated coverage of Royalty Pharma with a rating of Sector Outperform and set a new price target of $53.00

      5/13/22 7:24:42 AM ET
      $RPRX
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $RPRX
    Financials

    Live finance-specific insights

    See more
    • Royalty Pharma Reports First Quarter 2025 Results

      Portfolio Receipts growth of 17% to $839 million; Royalty Receipts growth of 12%Net cash provided by operating activities of $596 millionRaised full year 2025 guidance: Portfolio Receipts expected to be $2,975 to $3,125 million NEW YORK, May 08, 2025 (GLOBE NEWSWIRE) -- Royalty Pharma plc (NASDAQ:RPRX) today reported financial results for the first quarter of 2025 and raised full year 2025 guidance for Portfolio Receipts. "Our business momentum continued in the first quarter of 2025 as we delivered double-digit growth in Portfolio Receipts and raised our financial guidance," said Pablo Legorreta, Royalty Pharma's founder and Chief Executive Officer. "Guided by our dynamic capital allocat

      5/8/25 7:15:00 AM ET
      $RPRX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Royalty Pharma Declares Second Quarter 2025 Dividend

      NEW YORK, April 21, 2025 (GLOBE NEWSWIRE) -- The board of directors of Royalty Pharma plc (NASDAQ:RPRX) has approved the payment of a dividend for the second quarter of 2025 of $0.22 per Class A ordinary share. The dividend will be paid on June 10, 2025, to shareholders of record at the close of business on May 16, 2025. About Royalty Pharma Founded in 1996, Royalty Pharma is the largest buyer of biopharmaceutical royalties and a leading funder of innovation across the biopharmaceutical industry, collaborating with innovators from academic institutions, research hospitals and non-profits through small and mid-cap biotechnology companies to leading global pharmaceutical companies. Royal

      4/21/25 4:15:00 PM ET
      $RPRX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Royalty Pharma to Announce First Quarter 2025 Financial Results on May 8, 2025

      NEW YORK, April 17, 2025 (GLOBE NEWSWIRE) -- Royalty Pharma plc (NASDAQ:RPRX) today announced that it will report its first quarter 2025 financial results on Thursday, May 8, 2025 before the U.S. financial markets open. The company will host a conference call and simultaneous webcast at 8:30 a.m. Eastern Time that day. Conference Call Information Please visit the "Investors" page of the company's website at https://www.royaltypharma.com/investors/events/ to obtain conference call information and to view the live webcast. A replay of the conference call and webcast will be archived on the company's website for at least 30 days. About Royalty Pharma Founded in 1996, Royalty Pharm

      4/17/25 4:15:00 PM ET
      $RPRX
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $RPRX
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • Amendment: SEC Form SC 13G/A filed by Royalty Pharma plc

      SC 13G/A - Royalty Pharma plc (0001802768) (Subject)

      11/8/24 3:15:49 PM ET
      $RPRX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Amendment: SEC Form SC 13D/A filed by Royalty Pharma plc

      SC 13D/A - Royalty Pharma plc (0001802768) (Subject)

      7/29/24 4:30:11 PM ET
      $RPRX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form SC 13G/A filed by Royalty Pharma plc (Amendment)

      SC 13G/A - Royalty Pharma plc (0001802768) (Subject)

      2/13/24 10:17:30 AM ET
      $RPRX
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $RPRX
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Royalty Pharma Reports First Quarter 2025 Results

      Portfolio Receipts growth of 17% to $839 million; Royalty Receipts growth of 12%Net cash provided by operating activities of $596 millionRaised full year 2025 guidance: Portfolio Receipts expected to be $2,975 to $3,125 million NEW YORK, May 08, 2025 (GLOBE NEWSWIRE) -- Royalty Pharma plc (NASDAQ:RPRX) today reported financial results for the first quarter of 2025 and raised full year 2025 guidance for Portfolio Receipts. "Our business momentum continued in the first quarter of 2025 as we delivered double-digit growth in Portfolio Receipts and raised our financial guidance," said Pablo Legorreta, Royalty Pharma's founder and Chief Executive Officer. "Guided by our dynamic capital allocat

      5/8/25 7:15:00 AM ET
      $RPRX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • U.S. FDA Approves Second Drug Product Manufacturing Facility for ADSTILADRIN® (nadofaragene firadenovec-vncg)

      Ferring expands production of ADSTILADRIN with new Parsippany, NJ, facility, adding to existing manufacturing sites in Kuopio, Finland Capacity expansion and diversification of manufacturing footprint further ensures stable and sustainable supply to meet the anticipated growth in global demand for ADSTILADRIN Milestone prompts final $200 million payment from Royalty Pharma Ferring Pharmaceuticals announced today the U.S. Food and Drug Administration (FDA) approved a state-of-the-art drug product manufacturing hub in Parsippany, NJ, for its intravesical non-replicating gene therapy ADSTILADRIN® (nadofaragene firadenovec-vncg). The approval expands Ferring's manufacturing capabilities

      4/24/25 8:30:00 AM ET
      $RPRX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Royalty Pharma Declares Second Quarter 2025 Dividend

      NEW YORK, April 21, 2025 (GLOBE NEWSWIRE) -- The board of directors of Royalty Pharma plc (NASDAQ:RPRX) has approved the payment of a dividend for the second quarter of 2025 of $0.22 per Class A ordinary share. The dividend will be paid on June 10, 2025, to shareholders of record at the close of business on May 16, 2025. About Royalty Pharma Founded in 1996, Royalty Pharma is the largest buyer of biopharmaceutical royalties and a leading funder of innovation across the biopharmaceutical industry, collaborating with innovators from academic institutions, research hospitals and non-profits through small and mid-cap biotechnology companies to leading global pharmaceutical companies. Royal

      4/21/25 4:15:00 PM ET
      $RPRX
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $RPRX
    SEC Filings

    See more
    • SEC Form 10-Q filed by Royalty Pharma plc

      10-Q - Royalty Pharma plc (0001802768) (Filer)

      5/8/25 9:14:25 AM ET
      $RPRX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Royalty Pharma plc filed SEC Form 8-K: Results of Operations and Financial Condition

      8-K - Royalty Pharma plc (0001802768) (Filer)

      5/8/25 7:31:50 AM ET
      $RPRX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form DEFA14A filed by Royalty Pharma plc

      DEFA14A - Royalty Pharma plc (0001802768) (Filer)

      4/11/25 9:15:25 AM ET
      $RPRX
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $RPRX
    Leadership Updates

    Live Leadership Updates

    See more
    • Royalty Pharma Appoints Vlad Coric, M.D. to the Company's Board of Directors

      NEW YORK, April 08, 2025 (GLOBE NEWSWIRE) -- Royalty Pharma plc (NASDAQ:RPRX) today announced the appointment of Vlad Coric, M.D. to the company's Board of Directors, effective immediately. Vlad Coric is the Chairman and Chief Executive Officer of Biohaven, a biopharmaceutical company focused on the discovery, development and commercialization of life-changing treatments in key therapeutic areas including neuroscience, immunology and oncology. "I am excited to announce that we are strengthening our Board with the appointment of Vlad Coric," said Pablo Legorreta, founder and Chief Executive Officer of Royalty Pharma. "Vlad's entrepreneurial approach and outstanding leadership skills, hon

      4/8/25 4:15:00 PM ET
      $RPRX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Royalty Pharma Appoints Molly Sawaya as Executive Vice President, Head of Human Capital

      NEW YORK, July 24, 2024 (GLOBE NEWSWIRE) -- Royalty Pharma plc (NASDAQ:RPRX) today announced the appointment of Molly Sawaya as Executive Vice President, Head of Human Capital. Molly joins Royalty Pharma from Hudson Bay Capital, where she was a Managing Director and Head of Colleague Experience, responsible for designing and delivering the firm's Human Resources (HR) agenda, including onboarding, colleague engagement, professional development, compensation and benefits. Previously, Molly held a number of global HR roles of increasing responsibility at QBE Insurance Group, Perpetual Limited and National Australia Bank. Molly received her Bachelor of Arts and Master of Applied Science deg

      7/24/24 8:30:00 AM ET
      $RPRX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Royalty Pharma Appoints Eric Schneider as Chief Technology Officer

      NEW YORK, Sept. 21, 2023 (GLOBE NEWSWIRE) -- Royalty Pharma plc (NASDAQ:RPRX) today announced the appointment of Eric Schneider as Senior Vice President, Chief Technology Officer. Eric will also join Royalty Pharma's Senior Leadership Committee. Eric joins Royalty Pharma from Verisk, a global leader in data-driven analytic insights and solutions, where he was a Senior Vice President, Chief Data Officer and Chief Technology Officer, and a member of the Executive Leadership Team. During his tenure at Verisk, he led their migration to the cloud, mainframe modernization strategy and Data Governance and Data Strategy Team. Prior to Verisk, Mr. Schneider held senior IT leadership roles at Moody

      9/21/23 8:25:00 AM ET
      $RPRX
      Biotechnology: Pharmaceutical Preparations
      Health Care